2024 Arcutis biotherapeutics stock - Do the numbers hold clues to what lies ahead for the stock? Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended ...

 
Recent developments: Arcutis Biotherapeutics' stock rose 15% in early June after prescription data showed a 40% increase in Q1 for their psoriasis cream, Zoryve. Q1 2023 Earnings.. Arcutis biotherapeutics stock

Arcutis Biotherapeutics has received a new Buy rating, initiated by Mizuho Securities analyst, Uy Ear.Uy Ear’s rating for Arcutis Biotherapeutics is based on several crucial factors. One of the ...The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Arcutis Biotherapeutics stock price forecast: $51; Market Cap: 179.32M, Enterprise value: 934.67M, P/E: -2.1, PEG ratio: 0.05, EPS: -4.43, Revenue: 49.04M, ...Stockholder, Stake, Shares owned, Total value ($), Shares bought / sold, Total change. Suvretta Capital Management LLC, 10.19%, 9,592,212, 21,582,477 ...Latest News. November 15, 2022. Get Arcutis Biotherapeutics Inc (ARQT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Arcutis Biotherapeutics Stock Performance. ARQT opened at $2.34 on Monday. Arcutis Biotherapeutics has a 52-week low of $2.13 and a 52-week high of $20.11. The firm has a market capitalization of ...According to the issued ratings of 9 analysts in the last year, the consensus rating for Arcutis Biotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for ARQT. The average twelve-month price prediction for Arcutis Biotherapeutics is $29.67 with a high price target of $57.00 and a low price target of $6.00 ...WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. ARQT, an early commercial-stage biopharmaceutical company …WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA ...As of April 11, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.89. Arcutis Biotherapeutics Inc is up 4.2% from its previous closing price of $12.37. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.83 and $12.47. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ...0.50%. ¥2.18T. ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Arcutis Biotherapeutics Stock Forecast, ARQT stock price prediction. Price target in 14 days: 2.559 USD. The best long-term & short-term Arcutis ...Arcutis Biotherapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.914. Following the earnings report the stock price went up 9.91%. Which hedge fund is a major shareholder of Arcutis Biotherapeutics? Nov 29, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique ... NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown.Arcutis Biotherapeutics (ARQT) In a report released yesterday, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $57.00. The company’s ...Get the latest Arcutis Biotherapeutics, Inc. (ARQT) stock news and headlines to help you in your trading and investing decisions. ... Nov. 29, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc ...Arcutis common stock (ARQT) added to the Nasdaq Biotechnology Index Matthew Moore joined the Company as Chief Business Officer Completed underwritten public offering of common stock in February 2021 with gross proceeds of $221.4 million and net proceeds of $207.4 millionDec 1, 2023 · Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6 CI Nov. 13: Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight Rating In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less …Arcutis is selling 32,500,000 shares of common stock and, in lieu of common stock to certain investors, pre-fu. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics ...May 30, 2023 · As of May 30, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $7.81. Arcutis Biotherapeutics Inc is down 7.02% from its previous closing price of $8.40. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $8.11 and $8.57. Currently, there are 61.17 million shares of Arcutis Biotherapeutics Inc ... View the latest Arcutis Biotherapeutics Inc. (ARQT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Discover historical prices for ARQT stock on Yahoo Finance. View daily, weekly or monthly format back to when Arcutis Biotherapeutics, Inc. stock was issued.Dec 1, 2023 · Arcutis Biotherapeutics last posted its earnings data on November 3rd, 2023. The reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.17. The firm earned $38.11 million during the quarter, compared to the consensus estimate of $9.54 million. Arcutis Biotherapeutics has generated ($4. ... Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...Review which funds and institutions currently hold Arcutis Biotherapeutics Inc Ordinary Shares (ARQT:XNAS) stock for ownership information.Arcutis Biotherapeutics Stock Price, News & Analysis (NASDAQ:ARQT) $1.99 +0.15 (+8.15%) (As of 12/1/2023 ET) Compare Today's Range $1.76 $2.00 50-Day …7 thg 9, 2023 ... The healthcare company's stock closed last week at $8.96 a share and fell to as low as $7.47 on Thursday after Arcutis reported trial data ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ...Nov 8, 2022 · The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. Oct 9, 2023 · WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of ... Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » ARQT Arcutis …Arcutis Biotherapeutics, Inc. Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter ...Complete Arcutis Biotherapeutics Inc. stock information by Barron's. View real-time ARQT stock price and news, along with industry-best analysis.WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share ... Mar 22, 2023 · As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ... Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of April 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.03. Arcutis Biotherapeutics Inc is up 8.48% from its previous closing price of $11.09. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.67 and $11.23.4 ngày trước ... A rating of 29 puts Arcutis Biotherapeutics Inc (ARQT) near the top of the Healthcare sector according to Investor.Mar 7, 2023 · As of March 07, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $13.69. Arcutis Biotherapeutics Inc is down 5.85% from its previous closing price of $14.54. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $14.43 and $15.47. Currently, there are 61.04 million shares of Arcutis ... All of the shares of common stock and pre-funded warr. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial ...These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 14, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...After the upgrade, the seven analysts covering Arcutis Biotherapeutics are now predicting revenues of US$44m in 2023. If met, this would reflect a substantial 294% improvement in sales compared to ...Arcutis is selling 32,500,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,500,000 shares of common stock in the offering.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Arcutis Biotherapeutics (NASDAQ: ARQT) stock looks deeply undervalued after a correction of 65% in the last 12 months. However, it’s worth noting that even after the big downside, the short ...Do the numbers hold clues to what lies ahead for the stock? Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of 4.92% and 6.64%, respectively, for the quarter ended ...Sep 25, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17 with a high of $57.00 and a low of $22.00. As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ...Bioscience, applied to the skin. | Arcutis is addressing the innovation gap in medical #dermatology drug development. $ARQT #DermTwitter #Immunodermatology.66.61%. Get the latest Arcutis Biotherapeutics Inc (ARQT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ... Earlier this month, the company added to its pipeline assets by acquiring privately held Ducentis Biotherapeutics for an upfront cash payment of ~$16 million and Arcutis stock valued at ~$14 ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) | 16,482 followers on LinkedIn. Bioscience, applied to the skin. | Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant …See the company profile for Arcutis Biotherapeutics, Inc. (ARQT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ...Since the trade, Arcutis Biotherapeutics Inc's stock has declined by 20.89%, and it has plummeted by 91.54% since its IPO. The year-to-date performance is also down by 86.8%. With no applicable GF ...WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2023, and provided a business …As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45. Currently, there are 61.04 million shares of Arcutis ...Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Mar 18, 2023 · WESTLAKE VILLAGE, Calif., March 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today presented in a late-breaking clinical trial session at the American Academy of Dermatology (AAD) annual meeting (New Orleans, LA ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...All of the shares of common stock and pre-funded warr. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial ...Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 29, 2023 · RTTNews. Nov. 29, 2023, 08:24 AM. (RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT) announced the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the ... These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 0.76 and has seen 2.92 million shares traded in the last trading session. The company, currently valued at $187.82M, closed the last trade at $1.99 per share which meant it gained $0.15 on the day or 8.15% during that session. ... The ARQT stock price is -806.53% off its 52 …Find the latest Arcutis Biotherapeutics, Inc. (ARQT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.Track Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsArcutis is building momentum around its Zoryve segment with a string of recent advancements at the back end of FY22 and into the new year. Find out why ARQT stock is a Buy.ARCUTIS BIOTHERAPEUTICS INC Item 1(b) Address of issuer's principal executive offices: ----- 3027 TOWNSGATE ROAD, SUITE 300 WESTLAKE VILLAGE CA 91361 Item 2. 2(a) Name of person filing: ... Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c),Arcutis Biotherapeutics - ARQT - Stock Price Today - Zacks Arcutis Biotherapeutics (ARQT) (Real Time Quote from BATS) $1.99 USD +0.03 (1.53%) Updated Nov 28, 2023 10:40 AM ET Add to...At Arcutis, we fiercely value people—our patients, healthcare providers, team members, and our community at large. We aspire to be an upstanding global figure, with strong ethical standards embedded in our culture, and guiding our actions. We are a Great Place to Work ® -Certified company, a 2022 Fortune Best Workplaces in Biopharma™, and ...0.50%. ¥2.18T. ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. A. While ratings are subjective and will change, the latest Arcutis Biotherapeutics ( ARQT) rating was a maintained with a price target of $45.00 to $10.00. The current price Arcutis ...Arcutis Biotherapeutics Stock Performance. ARQT opened at $2.34 on Monday. Arcutis Biotherapeutics has a 52-week low of $2.13 and a 52-week high of $20.11. The firm has a market capitalization of ...As such, now is a great time to consider investing in Arcutis Biotherapeutics. Share Price. Arcutis Biotherapeutics had a rough first trading day on Monday. Its stock opened at $14.0 and closed at $13.3, a decrease of 3.8% from its previous closing price of $13.8. Despite this, investors should still consider investing in …Jun 9, 2023 · Shares of Arcutis Biotherapeutics ( ARQT -3.16%) climbed 21.2% for the week after rising as high as 23.8%, according to data provided by S&P Global Market Intelligence. The medical dermatology ... Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...0.50%. ¥2.18T. ARQT | Complete Arcutis Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nov. 29, 2023, 08:24 AM. (RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT) announced the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the treatment of ...Nov 02, 2023. Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Frank Watanabe. https://www.arcutis.com. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for …Which technical analysis tools can be used to analyze Arcutis Biotherapeutics, Inc.? Check out various oscillators, moving averages and other technical ...As of March 10, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.09. Arcutis Biotherapeutics Inc is down 5.03% from its previous closing price of $12.73. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $12.06 and $13.57. Currently, there are 61.04 million shares of Arcutis ...Arcutis biotherapeutics stock

Oct 13, 2023 · These 6 analysts have an average price target of $34.83 versus the current price of Arcutis Biotherapeutics at $3.3701, implying upside. Below is a summary of how these 6 analysts rated Arcutis ... . Arcutis biotherapeutics stock

arcutis biotherapeutics stock

Arcutis Biotherapeutics Stock Forecast, ARQT stock price prediction. Price target in 14 days: 2.559 USD. The best long-term & short-term Arcutis ...Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage. Resources. ... Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read More . Oct 25, 2023. Arcutis to Report Third Quarter 2023 Financial Results. Read More .Oct 9, 2023 · WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of ... In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price. Morgan Stanley, Cowen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.At Arcutis, we fiercely value people—our patients, healthcare providers, team members, and our community at large. We aspire to be an upstanding global figure, with strong ethical standards embedded in our culture, and guiding our actions. We are a Great Place to Work ® -Certified company, a 2022 Fortune Best Workplaces in Biopharma™, and ...The stock options have a ten-year term and an exercise price of $7.65 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on June 1, 2023. Arcutis is ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Oct 9, 2023 · Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $44.00. The associated price target is ... The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.One company hoping for such success is Arcutis Biotherapeutics (ARQT 4.08%). It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff ...Arcutis 4th Quarter and Full Year 2022 Financial Results & Business Update. 1.8 MB. Form 10-K. 6.5 MB. Q3. Arcutis Biotherapeutics, Inc. Q3 2022 Earnings Conference Call. Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update. Arcutis 3rd Quarter 2022 Financial Results & Business Update Presentation. 1.9 MB.According to 6 analyst offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17 with a high of $57.00 and a low of $22.00.Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 7.83 years. total yearly compensation is $4.58M, comprised of 12.9% salary and 87.1% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $798.75K. The average tenure of the management team and the board of ...Arcutis Biotherapeutics Inc (ARQT) Stock Price Today, Quote, Latest Discussions, Interactive Chart and News Advertisement 3rd Party Ad. Not an offer or recommendation …WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2023, and provided a business …WESTLAKE VILLAGE - Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of ...Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Arcutis Biotherapeutics Inc have a median target of 10.00, with a high estimate of ...Sep 29, 2022 · Arcutis Biotherapeutics' shares are down 15% year to date. Read more to see why ARQT stock is a buy for long-term investors. Arcutis Biotherapeutics' shares are down 15% year to date. Read more to ... Nov 29, 2023 · Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ... ARQT Stock Chart & Stats Advanced Chart > -74.69% Day’s Range $0 - $0 52-Week Range $1.77 - $18.19 Previous Close $2.03 Volume 1.23M Average Volume (3M) 2.25M …Arcutis Biotherapeutics Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 24%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Looking ahead, revenue ...Arcutis Biotherapeutics has received a new Buy rating, initiated by Mizuho Securities analyst, Uy Ear.Uy Ear’s rating for Arcutis Biotherapeutics is based on several crucial factors. One of the ...WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common …All of the shares of common stock and pre-funded warr. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial ...According to 6 analyst offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17 with a high of $57.00 and a low of $22.00.Arcutis Biotherapeutics rose $0.26 (+5.87%) to $4.69 on heavy volume today. That broke a streak of it falling for seven straight days. We'll see how this latest ...View the latest Arcutis Biotherapeutics Inc. (ARQT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Arcutis Biotherapeutics (NASDAQ:ARQT) has observed the following analyst ratings within the last quarter: These 6 analysts have an average price target of $34.83 versus the current price of ...Company profile page for Arcutis Biotherapeutics Inc including stock price, company news, executives, board members, and contact informationIn a report released today, Sean Kim PhD from JonesTrading reiterated a Buy rating on Arcutis Biotherapeutics ( ARQT – Research Report ), with a price target of $44.00. The company’s shares ...Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by …The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the commencement of an underwritten public offering of $150.0 ... Sean Kim PhD, an analyst from JonesTrading, reiterated the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $44.00. The associated price target is ...Aug 31, 2023 · Arcutis Biotherapeutics (NASDAQ: ARQT) stock looks deeply undervalued after a correction of 65% in the last 12 months. However, it’s worth noting that even after the big downside, the short ... Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...As of March 22, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $10.86. Arcutis Biotherapeutics Inc is down 6.06% from its previous closing price of $11.56. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.04 and $11.91. Currently, there are 61.04 million shares of Arcutis ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common …Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Arcutis Biotherapeutics ( ARQT – Research Report) today and set a price target of $50.00. The company’s shares closed yesterday ...That’s why we’re here. Arcutis has a passion for doing and delivering better through innovation. But not just for the sake of innovating—innovation that delivers the results that matter most. The kind that simplifies complex disease management and solves the most persistent challenges of treating chronic inflammatory diseases of the skin.Arcutis Biotherapeutics (ARQT) There’s also Arcutis Biotherapeutics (NASDAQ: ARQT ), a $217 million immuno-dermatology company, whose moderate-to-severe seborrheic dermatitis treatment will face ...May 30, 2023 · As of May 30, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $7.81. Arcutis Biotherapeutics Inc is down 7.02% from its previous closing price of $8.40. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $8.11 and $8.57. Currently, there are 61.17 million shares of Arcutis Biotherapeutics Inc ... Apr 18, 2023 · WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for ... May 30, 2023 · As of May 30, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $7.81. Arcutis Biotherapeutics Inc is down 7.02% from its previous closing price of $8.40. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $8.11 and $8.57. Currently, there are 61.17 million shares of Arcutis Biotherapeutics Inc ... Arcutis Announces Pricing of $100 Million Public Offering. WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningf... 4 weeks ago - GlobeNewsWire.The stock options have a ten-year term and an exercise price of $7.65 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on June 1, 2023. Arcutis is ...August 8, 2023 at 4:02 PM · 11 min read. Arcutis Biotherapeutics, Inc. Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream ...Dec 2, 2023 · The stock options have a ten-year term and an exercise price of $1.99 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on December 1, 2023. Arcutis Biotherapeutics (ARQT) Stock Price History Chart & Technical ...WESTLAKE VILLAGE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common …Nov 27, 2023 · The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The […] Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Oct 24, 2023 · After the upgrade, the seven analysts covering Arcutis Biotherapeutics are now predicting revenues of US$44m in 2023. If met, this would reflect a substantial 294% improvement in sales compared to ... See the latest Arcutis Biotherapeutics Inc Ordinary Shares stock price (ARQT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported, And Analysts Assigned A US$41.57 Price Target. (Simply Wall St.) Aug-10-23 08:16AM. Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia. (GlobeNewswire) Aug-09-23 09:23AM.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...Latest News. November 15, 2022. Get Arcutis Biotherapeutics Inc (ARQT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.What does smart money think about Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)? At Q1's end, a total of 8 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 8 from ...Complete Arcutis Biotherapeutics Inc. stock information by Barron's. View real-time ARQT stock price and news, along with industry-best analysis.Complete Arcutis Biotherapeutics Inc. stock information by Barron's. View real-time ARQT stock price and news, along with industry-best analysis. Nov. 29, 2023, 08:24 AM. (RTTNews) - Arcutis Biotherapeutics, Inc. (ARQT) announced the FDA has accepted its supplemental new drug application for roflumilast cream 0.15% for the treatment of ...Aug 10, 2023 · In the last 3 months, 7 analysts have offered 12-month price targets for Arcutis Biotherapeutics. The company has an average price target of $38.14 with a high of $57.00 and a low of $22.00. The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The simple moving average for the last 20 days is …Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. 66.61%. Get the latest Arcutis Biotherapeutics Inc (ARQT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ... As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45. Currently, there are 61.04 million shares of Arcutis ...Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Evolus, and ACADIA Pharmaceuticals. According to TipRanks , Ear has an average return of 7.3% and a 28.21% ...Oct 13, 2023 · These 6 analysts have an average price target of $34.83 versus the current price of Arcutis Biotherapeutics at $3.3701, implying upside. Below is a summary of how these 6 analysts rated Arcutis ... WESTLAKE VILLAGE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for .... Best 5g stocks